Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.63 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thebacon SCHEMBL21304123 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL25766 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL29632752 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL6240045 | 0.99 | OPRD1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL16922127 | 0.95 | OPRD1 (0.59) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18457704 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12944986 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL10222572 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18457702 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12006856 | 0.90 | OPRM1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | disclosed |
| US-20210061815-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2019165298-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2019-08-29 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061815-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.